| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2019 | IGE THERAPEUTICS INC | 11533 SPRUCE RUN DR | SAN DIEGO | CA | 92131-3728 | SAN DIEGO | USA | R44AI126680 | Broadly neutralizing(BN) pan-IgE supersite vaccine for allergic asthma | 000 | 3 | NIH | 4/19/2023 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2019 | IGE THERAPEUTICS, INC. | 11533 SPRUCE RUN DR | SAN DIEGO | CA | 92131-3728 | SAN DIEGO | USA | R44AI126680 | Broadly neutralizing(BN) pan-IgE supersite vaccine for allergic asthma | 000 | 3 | NIH | 7/2/2021 | $0 |
| | 2021 | 2018 | IGE THERAPEUTICS, INC. | 11533 SPRUCE RUN DR | SAN DIEGO | CA | 92131-3728 | SAN DIEGO | USA | R44AI122358 | CTL for supertype natural IgE cytotoxic peptide (nECP) to guard against allergic asthma | 000 | 3 | NIH | 11/20/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $982,439 ) |
| | 2019 | 2019 | IGE THERAPEUTICS, INC. | 11533 SPRUCE RUN DR | SAN DIEGO | CA | 92131-3728 | SAN DIEGO | USA | R44AI126680 | Broadly neutralizing(BN) pan-IgE supersite vaccine for allergic asthma | 000 | 3 | NIH | 2/12/2019 | $982,439 |
| | 2019 | 2018 | IGE THERAPEUTICS, INC. | 11533 SPRUCE RUN DR | SAN DIEGO | CA | 92131-3728 | SAN DIEGO | USA | R44AI122358 | CTL for supertype natural IgE cytotoxic peptide (nECP) to guard against allergic asthma | 000 | 3 | NIH | 7/18/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $1,362,730 ) |
| | 2018 | 2018 | IGE THERAPEUTICS, INC. | 11533 SPRUCE RUN DR | SAN DIEGO | CA | 92131-3728 | SAN DIEGO | USA | R44AI122358 | CTL for supertype natural IgE cytotoxic peptide (nECP) to guard against allergic asthma | 000 | 3 | NIH | 5/11/2018 | $549,186 |
| | 2018 | 2018 | IGE THERAPEUTICS, INC. | 11533 SPRUCE RUN DR | SAN DIEGO | CA | 92131-3728 | SAN DIEGO | USA | R44AI126680 | Broadly neutralizing(BN) pan-IgE supersite vaccine for allergic asthma | 000 | 2 | NIH | 2/8/2018 | $813,544 |
|
| Issue Date FY: 2017 ( Subtotal = $1,669,820 ) |
| | 2017 | 2017 | IGE THERAPEUTICS, INC. | 11533 SPRUCE RUN DR | SAN DIEGO | CA | 92131-3728 | SAN DIEGO | USA | R44AI126680 | Broadly neutralizing(BN) pan-IgE supersite vaccine for allergic asthma | 000 | 1 | NIH | 3/13/2017 | $813,544 |
| | 2017 | 2017 | IGE THERAPEUTICS, INC. | 11533 SPRUCE RUN DR | SAN DIEGO | CA | 92131-3728 | SAN DIEGO | USA | R44AI122358 | CTL for supertype natural IgE cytotoxic peptide (nECP) to guard against allergic asthma | 000 | 2 | NIH | 5/24/2017 | $856,276 |
|
| Issue Date FY: 2016 ( Subtotal = $853,476 ) |
| | 2016 | 2016 | IGE THERAPEUTICS INC | 6740 NANCY RIDGE DRIVE | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R44AI122358 | CTL for supertype natural IgE cytotoxic peptide (nECP) to guard against allergic asthma | 000 | 1 | NIH | 6/14/2016 | $853,476 |
|
| Issue Date FY: 2010 ( Subtotal = $702,036 ) |
| | 2010 | 2010 | IGE THERAPEUTICS INC | 6740 NANCY RIDGE DRIVE | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R43AI082770 | BI-FUNCTIONAL THERAPEUTICS FOR ALLERGY-BFTA | 001 | 2 | NIH | 9/1/2010 | $300,000 |
| | 2010 | 2010 | IGE THERAPEUTICS INC | 6740 NANCY RIDGE DRIVE | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R43AI084348 | TARGETING GALECTIN-3 WITH NOVEL DRUGS FOR TREATMENT OF ECZEMA | 000 | 2 | NIH | 6/14/2010 | $402,036 |
| | 2010 | 2009 | IGE THERAPEUTICS INC | 6740 NANCY RIDGE DRIVE | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R43AI082770 | BI-FUNCTIONAL THERAPEUTICS FOR ALLERGY-BFTA | 000 | 1 | NIH | 8/27/2010 | $0 |
|
| Issue Date FY: 2009 ( Subtotal = $701,647 ) |
| | 2009 | 2009 | IGE THERAPEUTICS INC | 6740 NANCY RIDGE DRIVE | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R43AI084348 | TARGETING GALECTIN-3 WITH NOVEL DRUGS FOR TREATMENT OF ECZEMA | 000 | 1 | NIH | 7/21/2009 | $401,647 |
| | 2009 | 2009 | IGE THERAPEUTICS INC | 6740 NANCY RIDGE DRIVE | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R43AI084348 | TARGETING GALECTIN-3 WITH NOVEL DRUGS FOR TREATMENT OF ECZEMA | 001 | 1 | NIH | 8/26/2009 | $0 |
| | 2009 | 2009 | IGE THERAPEUTICS INC | 6740 NANCY RIDGE DRIVE | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R43AI082770 | BI-FUNCTIONAL THERAPEUTICS FOR ALLERGY-BFTA | 000 | 1 | NIH | 9/28/2009 | $300,000 |
|
| Issue Date FY: 2004 ( Subtotal = $299,854 ) |
| | 2004 | 2004 | IGE THERAPEUTICS INC | 6827 NANCY RIDGE DRIVE | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R43AI054075 | ALLERGY PROTECTION BY ACTIVE IGE B CELL VACCINES | 000 | 2 | NIH | 12/4/2003 | $299,854 |
|
| Issue Date FY: 2003 ( Subtotal = $253,092 ) |
| | 2003 | 2003 | IGE THERAPEUTICS INC | 6827 NANCY RIDGE DRIVE | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R43AI054075 | ALLERGY PROTECTION BY ACTIVE IGE B CELL VACCINES | 000 | 1 | NIH | | $253,092 |
|
| Issue Date FY: 2002 ( Subtotal = $307,200 ) |
| | 2002 | 2002 | IGE THERAPEUTICS INC | 6827 NANCY RIDGE DRIVE | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R43AI049638 | ALLERGY PREVENTION BY LGE CYTOTOXIC PEPTIDE(ECP)VACCINE | 000 | 2 | NIH | 8/28/2002 | $307,200 |
|
| Issue Date FY: 2001 ( Subtotal = $232,200 ) |
| | 2001 | 2001 | IGE THERAPEUTICS INC | 6827 NANCY RIDGE DRIVE | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R43AI049638 | ALLERGY PREVENTION BY LGE CYTOTOXIC PEPTIDE(ECP)VACCINE | 000 | 1 | NIH | 9/27/2001 | $232,200 |
|
|
